-
Je něco špatně v tomto záznamu ?
Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study
MC. van Hooff, RC. de Veer, V. Karam, R. Adam, P. Taimr, WG. Polak, H. Pashtoun, SD. Murad, C. Corpechot, D. Mirza, M. Heneghan, P. Lodge, GC. Oniscu, D. Thorburn, M. Allison, HJ. Metselaar, CM. den Hoed, AJ. van der Meer, European Liver and...
Status neindexováno Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2019
PubMed Central
od 2019
ROAD: Directory of Open Access Scholarly Resources
od 2019
- Publikační typ
- časopisecké články MeSH
BACKGROUND & AIMS: Tacrolimus has been associated with recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT), which in turn may reduce survival. This study aimed to assess the association between the type of calcineurin inhibitor used and long-term outcomes following LT in patients with PBC. METHODS: Survival analyses were used to assess the association between immunosuppressive drugs and graft or patient survival among adult patients with PBC in the European Liver Transplant Registry. Patients who received a donation after brain death graft between 1990 and 2021 with at least 1 year of event-free follow-up were included. RESULTS: In total, 3,175 patients with PBC were followed for a median duration of 11.4 years (IQR 5.9-17.9) after LT. Tacrolimus (Tac) was registered in 2,056 (64.8%) and cyclosporin in 819 (25.8%) patients. Following adjustment for recipient age, recipient sex, donor age, and year of LT, Tac was not associated with higher risk of graft loss (adjusted hazard ratio [aHR] 1.07, 95% CI 0.92-1.25, p = 0.402) or death (aHR 1.06, 95% CI 0.90-1.24, p = 0.473) over cyclosporin. In this model, maintenance mycophenolate mofetil (MMF) was associated with a lower risk of graft loss (aHR 0.72, 95% CI 0.60-0.87, p <0.001) or death (aHR 0.72, 95% CI 0.59-0.87, p <0.001), while these risks were higher with use of steroids (aHR 1.31, 95% CI 1.13-1.52, p <0.001, and aHR 1.34, 95% CI 1.15-1.56, p <0.001, respectively). CONCLUSIONS: In this large LT registry, type of calcineurin inhibitor was not associated with long-term graft or recipient survival, providing reassurance regarding the use of Tac post LT in the population with PBC. Patients using MMF had a lower risk of graft loss and death, indicating that the threshold for combination treatment with Tac and MMF should be low. IMPACT AND IMPLICATIONS: This study investigated the association between immunosuppressive drugs and the long-term survival of patients with primary biliary cholangitis (PBC) following donation after brain death liver transplantation. While tacrolimus has previously been related to a higher risk of PBC recurrence, the type of calcineurin inhibitor was not related to graft or patient survival among patients transplanted for PBC in the European Liver Transplant Registry. Additionally, maintenance use of mycophenolate was linked to lower risks of graft loss and death, while these risks were higher with maintenance use of steroids. Our findings should provide reassurance for physicians regarding the continued use of Tac after liver transplantation in the population with PBC, and suggest potential benefit from combination therapy with mycophenolate.
Department of Hepatology and Liver Transplantation Royal Free Hospital London United Kingdom
Department of HPB Surgery Liver Unit Queen Elizabeth Hospital Birmingham United Kingdom
Division of Transplantation CLINTEC Karolinska Institutet Stockholm Sweden
Edinburgh Transplant Centre Royal Infirmary of Edinburgh Edinburg United Kingdom
European Society for Organ Transplantation Amsterdam The Netherlands
Inserm UMR_S938 Saint Antoine Research Center Sorbonne University Paris France
Institute of Liver Studies King's College Hospital London United Kingdom
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018113
- 003
- CZ-PrNML
- 005
- 20241016081841.0
- 007
- ta
- 008
- 241008s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jhepr.2024.101100 $2 doi
- 035 __
- $a (PubMed)39045337
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a van Hooff, Maria C $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 245 10
- $a Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study / $c MC. van Hooff, RC. de Veer, V. Karam, R. Adam, P. Taimr, WG. Polak, H. Pashtoun, SD. Murad, C. Corpechot, D. Mirza, M. Heneghan, P. Lodge, GC. Oniscu, D. Thorburn, M. Allison, HJ. Metselaar, CM. den Hoed, AJ. van der Meer, European Liver and Intestine Transplant Association (ELITA)
- 520 9_
- $a BACKGROUND & AIMS: Tacrolimus has been associated with recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT), which in turn may reduce survival. This study aimed to assess the association between the type of calcineurin inhibitor used and long-term outcomes following LT in patients with PBC. METHODS: Survival analyses were used to assess the association between immunosuppressive drugs and graft or patient survival among adult patients with PBC in the European Liver Transplant Registry. Patients who received a donation after brain death graft between 1990 and 2021 with at least 1 year of event-free follow-up were included. RESULTS: In total, 3,175 patients with PBC were followed for a median duration of 11.4 years (IQR 5.9-17.9) after LT. Tacrolimus (Tac) was registered in 2,056 (64.8%) and cyclosporin in 819 (25.8%) patients. Following adjustment for recipient age, recipient sex, donor age, and year of LT, Tac was not associated with higher risk of graft loss (adjusted hazard ratio [aHR] 1.07, 95% CI 0.92-1.25, p = 0.402) or death (aHR 1.06, 95% CI 0.90-1.24, p = 0.473) over cyclosporin. In this model, maintenance mycophenolate mofetil (MMF) was associated with a lower risk of graft loss (aHR 0.72, 95% CI 0.60-0.87, p <0.001) or death (aHR 0.72, 95% CI 0.59-0.87, p <0.001), while these risks were higher with use of steroids (aHR 1.31, 95% CI 1.13-1.52, p <0.001, and aHR 1.34, 95% CI 1.15-1.56, p <0.001, respectively). CONCLUSIONS: In this large LT registry, type of calcineurin inhibitor was not associated with long-term graft or recipient survival, providing reassurance regarding the use of Tac post LT in the population with PBC. Patients using MMF had a lower risk of graft loss and death, indicating that the threshold for combination treatment with Tac and MMF should be low. IMPACT AND IMPLICATIONS: This study investigated the association between immunosuppressive drugs and the long-term survival of patients with primary biliary cholangitis (PBC) following donation after brain death liver transplantation. While tacrolimus has previously been related to a higher risk of PBC recurrence, the type of calcineurin inhibitor was not related to graft or patient survival among patients transplanted for PBC in the European Liver Transplant Registry. Additionally, maintenance use of mycophenolate was linked to lower risks of graft loss and death, while these risks were higher with maintenance use of steroids. Our findings should provide reassurance for physicians regarding the continued use of Tac after liver transplantation in the population with PBC, and suggest potential benefit from combination therapy with mycophenolate.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a de Veer, Rozanne C $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a Karam, Vincent $u European Society for Organ Transplantation, Amsterdam, The Netherlands
- 700 1_
- $a Adam, Rene $u European Liver Transplant Registry, Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation AP-HP Hôpital Paul Brousse, Université Paris-Saclay Villejuif, France
- 700 1_
- $a Taimr, Pavel $u Department of Hepatology and Gastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Polak, Wojciech G $u Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a Pashtoun, Hasina $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a Murad, Sarwa Darwish $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a Corpechot, Christophe $u Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France
- 700 1_
- $a Mirza, Darius $u Department of HPB Surgery, Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom
- 700 1_
- $a Heneghan, Michael $u Institute of Liver Studies, King's College Hospital, London, United Kingdom
- 700 1_
- $a Lodge, Peter $u The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
- 700 1_
- $a Oniscu, Gabriel C $u Edinburgh Transplant Centre, Royal Infirmary of Edinburgh, Edinburg, United Kingdom $u Division of Transplantation, CLINTEC, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Thorburn, Douglas $u Department of Hepatology and Liver Transplantation, Royal Free Hospital, London, United Kingdom
- 700 1_
- $a Allison, Michael $u Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge NIHR Biomedical Research Centre, Cambridge, United Kingdom
- 700 1_
- $a Metselaar, Herold J $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a den Hoed, Caroline M $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 700 1_
- $a van der Meer, Adriaan J $u Department of Gastroenterology and Hepatology, Erasmus MC Transplant Institute, University Medical Center Rotterdam, The Netherlands
- 710 2_
- $a European Liver and Intestine Transplant Association (ELITA)
- 773 0_
- $w MED00210139 $t JHEP reports $x 2589-5559 $g Roč. 6, č. 8 (2024), s. 101100
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39045337 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081836 $b ABA008
- 999 __
- $a ok $b bmc $g 2196462 $s 1230064
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 6 $c 8 $d 101100 $e 20240425 $i 2589-5559 $m JHEP reports $n JHEP Rep $x MED00210139
- LZP __
- $a Pubmed-20241008
